CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
February 28, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
February 22, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Announces New Employment Inducement Grants
February 16, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer
February 07, 2022 09:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the...
CytomX Therapeutics Announces New Employment Inducement Grants
January 20, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that on...
CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors
January 19, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S....
CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean...
CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71
December 20, 2021 16:05 ET
|
CytomX Therapeutics Inc.
-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues- -Enrollment completed in advanced...
CytomX Therapeutics to Present at Upcoming November Investor Conferences
November 11, 2021 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean...
CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021 16:15 ET
|
CytomX Therapeutics Inc.
-Initial data release from Phase 2 study of CX-2029 remains on track for fourth quarter 2021- -Initial data release from Phase 2 study of praluzatamab ravtansine (CX-2009) expected in 2022- ...